About Our Investors
Amplitude Ventures
Amplitude is a full-stack venture capital firm using a unique growth model to build Canadian companies with world-class management teams and scale companies to breakout potential. With over $300M under management and offices in Montreal, Toronto and Vancouver, Amplitude applies a proven, evidence- based approach to investing in leading precision medicine companies. Visit www.amplitudevc.com
The Fonds de solidarité FTQ
The Fonds de solidarité FTQ invests to build a better society by channeling the savings of its 723,501 shareholders into development and risk capital investments to help Québec transition to a green economy, to a human-centered world of work, and to a healthier society. The Fonds offers businesses unsecured financing and strategic support. With $17.2 billion in net assets as at May 31, 2021, the Fonds has supported 3,437 partner companies and 247,612 jobs. Visit www.fondsftq.com
Lumira Ventures
Lumira Ventures is a North American healthcare venture capital firm with a two-decade track record of investing in transformative biomedical companies. It is a multi-stage investor that partners with mission-driven entrepreneurs and like-minded investors to build innovative companies in the biotechnology, medical device and digital health sectors. These companies are harnessing rapidly evolving innovations in genomics, cell therapy, gene therapy, bioengineering, robotics and artificial intelligence to develop high impact, often transformative products for patients while generating exceptional returns for their investors and meaningful economic value to society. To date, Lumira’s companies have brought dozens of biomedical innovations to the market, impacting the lives of over 1 billion patients worldwide and generating over $70 billion of cumulative revenue. Lumira Ventures manages its activities from offices in Toronto, Montréal, Vancouver and Boston. Visit www.lumiraventures.com
Amzak Health
Amzak Health is an evergreen fund that invests in private and select public life science companies across stages and geographies. It seeks to invest in innovative biotech and medtech companies developing first in class or best in class treatments addressing areas of unmet medical need. The Amzak Health team has significant investment and operating experience. Amzak Health approaches each investment with a long-term vision and prides itself on being knowledgeable and dependable partners. Amzak Heath is based in New York. Visit www.amzak.com
Alexandria Venture Investments
Alexandria Venture Investments is the Alexandria Real Estate’s strategic venture capital platform. Since its inception in 1996, it has invested in disruptive life science, agrifoodtech, and technology companies advancing transformative new modalities and platforms to meaningfully improve human health. Visit www.are.com
adMare BioInnovations
With a wealth of scientific discovery, Canada is primed to be a global leader in life sciences. To realize this potential, adMare uses its scientific and commercial expertise, specialized R&D infrastructure, and investment capital to build investable companies, robust ecosystems and industry-ready talent – and re-invests its returns back into the Canadian industry to ensure it is sustained for the long-term. Visit www.admarebio.com
Investissement Québec
Investissement Québec’s mission is to play an active role in Quebec’s economic development by stimulating business innovation, entrepreneurship and business acquisitions, as well as growth in investment and exports. Operating in all of the province’s administrative regions, the Corporation supports the creation and growth of businesses of all sizes with investments and customized financial solutions. It also assists businesses by providing consulting services and other support measures, including technological assistance available from Investissement Québec – CRIQ. In addition, through Investissement Québec International, the Corporation prospects for talent and foreign investment, and assists Quebec businesses with export activities. Visit Investissement Québec
CTI Life Sciences Fund
CTI Life Sciences Fund is a knowledge-driven boutique venture capital firm. We leverage our deep, complementary, and collective intelligence to deliver strong results on investments in Life Sciences. Our mission is to catalyze emerging science, transform business objectives, and invest in scalable companies within Canada, the United States and Europe. In doing so, we aim to deliver impactful innovations and strong returns to a large sphere of stakeholders across biotechnology and healthcare.
About Thryv Therapeutics
Thryv Therapeutics Inc. (previously LQT Therapeutics Inc.), is a privately owned company based in Montreal, Quebec, Canada. They have been pioneering a precision medicine approach to treat Long QT Syndrome via SGK1 inhibition since 2019 and have since evolved their portfolio to include the treatment of resistant and rare cancers. The development of SGK1 inhibitors represents a novel approach to target treatment-resistant cancers, and complement existing therapies. This strategic evolution has secured an additional US$15M financing fuelling Thryv to complete a proof-of-concept study for LQTS, and submit an IND for the treatment of resistant cancer.